Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berzosertib and Irinotecan in Advanced Solid Tumors
NCT02595931Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2016
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of berzosertib in solid tumor, sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase 2 Dose at 28 days. Started Jul 2016; status: active, not recruiting.
02
Drugs
berzosertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02595931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595931.